The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Open accessAbstract
Introduction: Venetoclax (VEN), a selective BCL2 inhibitor, has single‐agent activity in relapsed and refractory (R/R) acute myeloid leukemia (AML), and efficacy in lower intensity combinations for treatment‐naïve elderly AML patients. VEN treatment combinations in R/R AML have not been previously reported. Methods: All R/R myeloid patients (including AML, myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN)) treated with VEN combinations in the salvage setting were reviewed. Results: Forty‐three patients with median age 68 (range, 25–83) were treated for AML (91%), MDS (5%), or BPDCN (5%). Most (n = 36, 84%) were ≥ salvage‐2 treatment status, including prior hypomethylating agent (HMA) in 77%. In combination with VEN, most patients received HMA therapy (n = 31, 72%); eight (19%) received low‐dose cytarabine (LDAC). Patients received a median of 2 treatment cycles (range, 1–4). Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS). Median survival was 3.0 months (range, 0.5–8.0), and estimated 6‐month survival was 24%. Responses were observed in five (24%) of 21 patients with intermediate‐risk cytogenetics, 3 (27%) of 11 IDH1/2‐mutant, and 4 (50%) of 8 RUNX1‐mutated patients. Two (20%) of 10 TP53‐mutated patients responded; both had concurrent RUNX1 mutations. Of the 3 (15%) responding patients with adverse cytogenetics, all had concurrent RUNX1 mutations. Conclusion: Low‐intensity chemotherapy, including HMAs or LDAC, in combination with VEN is a viable salvage option, even in multiply relapsed/refractory patients with AML, MDS, and BPDCN. Notable responses were identified in patients with diploid/intermediate cytogenetics, RUNX1, and/or IDH1/2 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Self-citationAge and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,350
Konopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
Self-citationSelective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
Self-citationOlsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., Lessin, S. R., Wood, G. S., Willemze, R., Demierre, M.-F., Pimpinelli, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0630 · Cited by 666
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., Zhao, F., Medeiros, B. C., Tyvoll, D. A., & Majeti, R. (2015) · Nature Medicine · doi:10.1038/nm.3788 · Cited by 577
Parker, J. E., Mufti, G. J., Rasool, F., Mijovic, A., Devereux, S., & Pagliuca, A. (2000) · Blood · doi:10.1182/blood.v96.12.3932 · Cited by 363
Vo, T.-T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348
Fröhling, S., Schlenk, R. F., Kayser, S., Morhardt, M., Benner, A., Döhner, K., Döhner, H., & for the German-Austrian AML Study Group (2006) · Blood · doi:10.1182/blood-2006-04-014324 · Cited by 300
Agarwal, S. K., DiNardo, C. D., Potluri, J., Dunbar, M., Kantarjian, H. M., Humerickhouse, R. A., Wong, S. L., Menon, R. M., Konopleva, M. Y., & Salem, A. H. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.003 · Cited by 237
Self-citationBlastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Montero, J., Stephansky, J., Cai, T., Griffin, G. K., Cabal-Hierro, L., Togami, K., Hogdal, L. J., Galinsky, I., Morgan, E. A., Aster, J. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0999 · Cited by 212
Self-citationGemtuzumab ozogamicin in acute myeloid leukemia
Godwin, C. D., Gale, R. P., & Walter, R. B. (2017) · Leukemia · doi:10.1038/leu.2017.187 · Cited by 210
Survival and cure of acute myeloid leukaemia in England, 1971‐2006: a population–based study
Shah, A., Andersson, T. M. ‐., Rachet, B., Björkholm, M., & Lambert, P. C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12425 · Cited by 206
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells
Goyama, S., Schibler, J., Cunningham, L., Zhang, Y., Rao, Y., Nishimoto, N., Nakagawa, M., Olsson, A., Wunderlich, M., Link, K. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68557 · Cited by 196
Outcome of older patients with acute myeloid leukemia: An Analysis of SEER Data Over 3 Decades
Thein, M. S., Ershler, W. B., Jemal, A., Yates, J. W., & Baer, M. R. (2013) · Cancer · doi:10.1002/cncr.28129 · Cited by 192
Tsao, T., Shi, Y., Kornblau, S., Lu, H., Konoplev, S., Antony, A., Ruvolo, V., Qiu, Y. H., Zhang, N., Coombes, K. R., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1537-8 · Cited by 171
Self-citationKonopleva, M., Zhao, S., Hu, W., Jiang, S., Snell, V., Weidner, D., Jackson, C. E., Zhang, X., Champlin, R., Estey, E., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03637.x · Cited by 171
Self-citationBogenberger, J. M., Delman, D., Hansen, N., Valdez, R., Fauble, V. D. S., Mesa, R. A., & Tibes, R. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.910657 · Cited by 152
Jilg, S., Reidel, V., Müller‐Thomas, C., König, J., Schauwecker, J., Höckendorf, U., Huberle, C., Gorka, O., Schmidt, B., Burgkart, R., et al. (2015) · Leukemia · doi:10.1038/leu.2015.179 · Cited by 107
Agarwal, S. K., Salem, A. H., Danilov, A. V., Hu, B., Puvvada, S. D., Gutierrez, M. E., Chien, D. C., Lewis, L. D., & Wong, S. L. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13175 · Cited by 107
Wei, A. H., Strickland, S. A., Roboz, G. J., Hou, J., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A. K., Chyla, B., Popovic, R., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.890.890 · Cited by 58
Cited by
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
Jones, C. L., Stevens, B. M., D'Alessandro, A., Reisz, J. A., Culp-Hill, R., Nemkov, T., Pei, S., Khan, N., Adane, B., Ye, H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.005 · Cited by 585
Daver, N., Garcia-Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M., Ravandi-Kashani, F., Jabbour, E., Kadia, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0774 · Cited by 555
Self-citationAcute myeloid leukemia: 2019 update on risk‐stratification and management
Estey, E. H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25214 · Cited by 371
DiNardo, C. D., Maiti, A., Rausch, C. R., Pemmaraju, N., Naqvi, K., Daver, N. G., Kadia, T. M., Borthakur, G., Ohanian, M., Alvarado, Y., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30210-6 · Cited by 324
Self-citationPrimary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26050 · Cited by 315
Metadata
- Authors
- DiNardo, C. D., Rausch, C. R., Benton, C., Kadia, T., Jain, N., Pemmaraju, N., Daver, N., Covert, W., Marx, K. R., Mace, M., Jabbour, E., Cortes, J., Garcia‐Manero, G., Ravandi, F., Bhalla, K. N., Kantarjian, H., & Konopleva, M.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2017-12-23
- Volume
- 93
- Issue
- 3
- Pages
- 401-407
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2774533007
- Cited by
- 424
- References
- 27
- FWCI
- 28.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.